Year-end report 2017

2018-02-21 | Regulatory

SUMMARY OF THE PERIOD 

Important events during the fourth quarter 2017

  • In December, Vicore Pharma Holding increased its holding in I-Tech AB through a share issue.
  • In December, Vicore Pharma submitted an application to the British authorities to start a phase IIa study in patients suffering from idiopathic pulmonary fibrosis (IPF).
  • In December, Vicore Pharma’s board member, Göran Arvidson, passed away.
  • In October, Vicore Pharma announced results from the in-depth analysis of the Phase I extension study. The results verified previously published data that C21 has beneficial effects on lipid metabolism. It is a first demonstration of pharmacodynamic effects in man for C21 and indeed for the pharmacological principle of AT2 receptor stimulation

Important events after the period

  • In February, Vicore Pharma Holding increased its holding in I-Tech AB by acquiring shares from an existing shareholder in I-Tech. Thereafter, Vicore Pharma Holding owns 26.5% of the shares in I-Tech.

Financial summary 

KSEK Oct-Dec
2017
Oct-Dec
2016
Year
2017
Year
2016
Operating profit/loss -2 082 -1 802 -8 594 -6 649
Profit/loss after financial items -15 712 -1 802 -22 285 -6 652
Earnings per share, SEK -0,99 -0,15 -1,40 -0,54
Equity as per 31 december 103 539 75 597 103 539 75 597
Cash flow from operating activities 706 201 -7 703 -7 289
Cash flow from investing activities -9 115 -4 855 -22 780 -13 940
Cash and cash equivalents as per 31 December 24 019 4 266 24 019 4 266

CEO COMMENTS

Fourth quarter: Application for phase IIa study submitted
In December, Vicore Pharma submitted an application to start a phase IIa study with C21 in our lead indication, idiopathic pulmonary fibrosis (IPF). The application was prepared together with our CRO (Contract Research Organisation), PAREXEL. This is an important step for us and we look forward to start the study as soon as the necessary approvals are at hand.

Summary of 2017
As previously communicated, we updated our strategy during the autumn 2017. We are now focused on developing C21 for fibrotic diseases with orphan drug designation. Based on the underlying data we have generated over the years, we have selected idiopathic pulmonary fibrosis (IPF) as the first indication in which to start a phase IIa study. During the spring 2017, when we conducted a BioMAP® study with the purpose to investigate the anti-fibrotic properties for C21 in human cells. BioMAP is a screening study where human lung cells are exposed to fibrosing compounds whereafter these cells can be used to evaluate possible effects in test substances. Data from the study confirms that C21 exerts its positive antifibrotic effects in primary human cells, further giving strength to the well documented antifibrotic effects already demonstrated in fibrotic animal models. C21 exerted stronger anti-inflammatory and antifibrotic effects compared to the two approved IPF drugs. In January 2017, Vicore Pharma was granted orphan drug designation for C21 from the FDA in the USA. C21 holds the corresponding orphan drug status in the EU since 2016.

As part of the continued development and entering a new clinical phase, we strengthened our organisation during the summer with three key recruitments: Kicki Johansson as Head of Drug Development; Hans Jeppsson as CFO; and Ulrike Muscha Steckelings as CSO.

We were saddened to receive the news of the passing in December of our board member, Göran Arvidson. The nomination committee intend to seek a successor to the next AGM in May 2018.

To strengthen our capital position, Vicore Pharma Holding gained 56 MSEK during the spring from two directed share issues to institutional Swedish and international investors.

Associate company, I-Tech
In December, Vicore Pharma Holding increased its holding in I-Tech AB to 21% through a share issue. After the period, in February, Vicore Pharma Holding and the majority of the shareholders in I-Tech, in accordance to the company’s pre-emption rights further increased our holding  by acquiring shares from a long-standing shareholder in I-Tech. Our holding in I-Tech is now 26.5%.  I-Tech is now an associate company and is accounted for in the group accounts in accordance with the equity method. This means there is a negative effect of 13,6 MSEK on our profit for the period.

I-Tech has developed Selektope®, an approved bio-repellent substance that protects boat and ship hulls from barnacle settlement. Selektope® is used as a strategic biocide in antifouling coatings. Selektope® is sold to companies that manufacture marine coatings for commercial shipbuilding and repair. There are currently 6 registered marine coatings containing Selektope on the market in Asia.

I-Tech has had an eventful 2017. The company has gained a new customer in coating company, Hempel, which has launched an outfitting coating containing Selektope®. Another existing customer, Chugoku Marine Paints, has  extended its product range during 2017 with another product containing Selektope®. A Swedish shipping company, Stena RoRo, signed a contract to coat the hulls of four newbuild ferries with a Selektope®-based coating. High demand for Selektope® has led to I-Tech signing agreements with import agents in Japan to strengthen our supply chains. During the year, I-Tech has made new recruitments to bring onboard new skills adapted to the excting growth phase the company is currently in.

The significant progress made during 2017, which paves the way for further positive development of I-Tech, was the key factor in Vicore Pharma Holding’s decision to participate in the share issue I-Tech conducted at the end of 2017, and to then later also acquire shares from an existing shareholder in I-Tech.

Looking to the future
During 2018, together with our CRO, our focus will be to initiate the phase IIa IPF study. More details on the implemention of the study will be communicated during the spring. We continue to work with qualified researchers, clinicians and specialists in drug development to select a second indication to develop. 

We sincerely thank all our shareholders for their support during the past year. We look forward to continuing to build more value for Vicore Pharma Holding!

Per Jansson, CEO 

For further information, please contact: 

Per Jansson, CEO
Tel: +46 709 17 47 46 or e-mail: per.jansson@vicorepharma.com 
 

Hans Jeppsson, CFO
Tel: +46 705 53 14 65 or e-mail: hans.jeppsson@vicorepharma.com
 

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08.00 CET on February 21, 2018


Vicorepharma

On vicorepharma.com, we use so-called cookies to analyze how our website is used in order to optimize and improve it. You choose yourself whether you want to consent to our use of cookies.

Vicorepharma is responsible for placing cookies on the website and for the processing of your personal data collected by them. For more information about our processing of your personal data, see our privacy policy

Cookie policy

Your consent applies to the following domain: vicorepharma.com
The cookie policy was last updated: 2023-01-24

Privacy Policy

Show the cookies used on our website

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Marketing cookies is used to track visitors on the website. The intention is to show ads that are relevant and engaging to the individual user and thus be more valuable to publishers and third-party advertisers.

  • AMP_TOKEN

    Purpose: Contains a token that can be used to retrieve a unique user ID.
    Issued by: AMP
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _fbp

    Purpose: Used to store and track visits across websites.
    Issued by: Facebook
    Lifespan: 3 months

    Domain: vicorepharma.com

  • _gac_

    Purpose: Used to store and track audience reach.
    Issued by: Google Ads
    Lifespan: 90 days

    Domain: vicorepharma.com

  • _lfa

    Purpose: Used to store and track audience reach.
    Issued by: Leadfeeder
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _lfa_test_cookie_stored

    Purpose: Used to test if _lfa was stored.
    Issued by: Leadfeeder
    Lifespan: 1 day

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _clck

    Purpose: Used to store a unique user ID.
    Issued by: Microsoft Clarity
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _clsk

    Purpose: Used to store and combine pageviews by a user into a single session recording.
    Issued by: Microsoft Clarity
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _hjAbsoluteSessionInProgress

    Purpose: Used to store unique visits.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjFirstSeen

    Purpose: Used to identify a new visitors’ first session.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

  • _hjid

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjIncludedInPageviewSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily pageview limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjIncludedInSessionSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily session limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjSessionUser{site_id}

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjSession{site_id}

    Purpose: A cookie that holds the current session data.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjTLDTest

    Purpose: Used to check if cookies can be loaded on the site and is removed shortly afterward.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

What are cookies?

A cookie is a small text file that is placed on your device (computer/mobile/tablet that has access to the internet) by the website you visit – if you give your consent to this. The cookie can, for example, recognize you as a user when you visit our website and make it possible to remember important information that makes your visit more comfortable and provides an improved user experience. Cookies are so-called passive files that cannot spread dangerous software or viruses on your mobile device or computer.

 

There are two types of cookies, permanent cookies and session cookies. At vicorepharma.com we use both permanent cookies and session cookies. Permanent cookies are saved as a file on the computer for a certain time until the server that placed them, or you as a visitor choose to delete them. Session cookies are temporarily stored when you as a visitor are on the website and disappear when you close your browser.

 

Cookies can also be divided into first-party cookies and third-party cookies. First-party cookies are placed by the website you are visiting, while third-party cookies are placed by another website. At vicorepharma.com, we use both first-party cookies and third-party cookies.

 

How to avoid cookies

When you visit our website, you can refuse all or certain types of cookies. You can also withdraw or change your consent at any time by clicking here.

 

You can also block cookies by changing the settings in your browser. Then your browser will automatically refuse cookies or inform you when a website requests to store cookies.

 

After your visit, you can review and delete the permanent cookies that have been stored in your browser. In the list below, you will see the name of the cookies vicorepharma.com saves so that you can easily identify them.

 

Here you will find more information about how to manage cookies in your browser:

 

Cookies used by third parties

On vicorepharma.com there may be content that is embedded from YouTube. YouTube places cookies in your browser when you visit youtube.com or when you click on embedded content from YouTube on our website. vicorepharma cannot control these cookies or the personal data and information that may be collected. vicorepharma does not use the targeted marketing services offered by YouTube. As a user, you therefore need to check YouTube’s website for further information on how they manage cookies, what information they collect and how you can delete any third-party cookies.

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Marketing cookies is used to track visitors on the website. The intention is to show ads that are relevant and engaging to the individual user and thus be more valuable to publishers and third-party advertisers.

  • AMP_TOKEN

    Purpose: Contains a token that can be used to retrieve a unique user ID.
    Issued by: AMP
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _fbp

    Purpose: Used to store and track visits across websites.
    Issued by: Facebook
    Lifespan: 3 months

    Domain: vicorepharma.com

  • _gac_

    Purpose: Used to store and track audience reach.
    Issued by: Google Ads
    Lifespan: 90 days

    Domain: vicorepharma.com

  • _lfa

    Purpose: Used to store and track audience reach.
    Issued by: Leadfeeder
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _lfa_test_cookie_stored

    Purpose: Used to test if _lfa was stored.
    Issued by: Leadfeeder
    Lifespan: 1 day

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _clck

    Purpose: Used to store a unique user ID.
    Issued by: Microsoft Clarity
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _clsk

    Purpose: Used to store and combine pageviews by a user into a single session recording.
    Issued by: Microsoft Clarity
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _hjAbsoluteSessionInProgress

    Purpose: Used to store unique visits.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjFirstSeen

    Purpose: Used to identify a new visitors’ first session.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

  • _hjid

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjIncludedInPageviewSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily pageview limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjIncludedInSessionSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily session limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjSessionUser{site_id}

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjSession{site_id}

    Purpose: A cookie that holds the current session data.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjTLDTest

    Purpose: Used to check if cookies can be loaded on the site and is removed shortly afterward.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

General

Vicore Pharma Holding AB (“Vicore”) shall only process personal data in accordance with applicable data protection law and high industry standards.

 

Personal data.

Vicore processes personal data provided to us;
(i) by you in the day-to-day communications, or

(ii) in connection with entering into or performing an agreement or business arrangement with you, or
(iii) by a third party allowed by law or your consent.

The personal data may consist of contact and identification details and other information relevant to the situation.

 

Purpose.

Vicore process personal data for the purpose of communicating with you and to perform, manage and comply with agreements between us as well as rights and obligations which are allowed by law or applicable regulation.

 

Legal grounds.

The legal grounds for processing personal data is either;
(i) your consent which shall be considered provided when you either voluntary submit the personal data or enter into an agreement with us, or
(ii) a legitimate interest allowed under law.

 

Security

Vicore shall use adequate technical and organisational security measures to protect the personal data from loss and to safeguard against access from unauthorised persons.

Transfers of personal data may only occur;
(i) to third parties who perform services on Vicore behalf and who may only process personal data in accordance with our instructions, and may not use personal data for their own purposes; and
(ii) outside the EU/EEA only in accordance with applicable data protection laws and subject to the EU Commission’s standard contractual clauses, and
(iii) as otherwise permitted by law or your consent.

Duration.

The duration we process personal data is limited to what is reasonable for the purpose of the processing, unless otherwise required or permitted by law.

 

Rights

Vicore is the controller of the personal data processing, meaning that we are responsible for that the personal data is processed correctly and in accordance with applicable data protection laws.

Unless prevented by applicable law, regulation or agreement data subjects have the right to;
(i) know what personal data we process about them,
(ii) request that we rectify or erase inaccurate or incomplete personal data
(iii) object to specific processing of personal data, and
(iv) receive the personal data provided by them and have the personal data transferred to another party responsible for data processing.

All communications with Vicore regarding how we process personal data or exercise of any of your rights can be sent by e-mail to info@vicorepharma.com or by post to the address above.

Reports and complaints can also be directed to Datainspektionen who is the supervisory authority for our processing of personal data.